Citation Impact
Citing Papers
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy
2020
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
2022
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities
2017
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Opportunities for Treg cell therapy for the treatment of human disease
2023 StandoutNobel
Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation
2018
A journey through infectious risk associated with ruxolitinib
2019
Works of Haris Ali being referenced
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
2018
A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)
2016
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
2020
Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells
2015
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
2020